Incidence of nephrogenic systemic fibrosis in patients undergoing dialysis after contrast-enhanced magnetic resonance imaging with gadolinium-based contrast agents: The prospective fibrose nephrogénique systémique study

Investigative Radiology

Volumn 49, Issue 2, 2014, Pages 109-115

  Amet, Sabine ^a   Launay Vacher, Vincent ^a   Clément, Olivier ^b   Frances, Camille ^c   Tricotel, Aurore ^d   Stengel, Benedicte ^e   Gauvrit, Jean Yves ^f   Grenier, Nicolas ^g   Reinhardt, Geneviève ^h   Janus, Nicolas ^a   Choukroun, Gabriel ⁱ   Laville, Maurice ^j   Deray, Gilbert ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^c HÔPITAL TENON   (France)

^d Service de pharmacovigilance   (France)

^e HÔPITAL PAUL BROUSSE   (France)

^f PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

^g HÔPITAL PELLEGRIN   (France)

^h Service de radiologie   (France)

ⁱ AMIENS UNIVERSITY HOSPITAL   (France)

^j CENTRE HOSPITALIER LYON SUD   (France)

more..

Author keywords

Dialysis; End stage renal disease; Gadolinium based contrast agents; Gadoteric acid; Macrocyclic agents; Magnetic resonance imaging; Nephrogenic systemic fibrosis

Indexed keywords

GADOBENATE DIMEGLUMINE; GADOBUTROL; GADODIAMIDE; GADOLINIUM; GADOLINIUM PENTETATE MEGLUMINE; GADOTERATE MEGLUMINE; GADOTERIDOL; GADOVERSETAMIDE;

ADULT; AGED; ARTICLE; CONTRAST ENHANCEMENT; FEMALE; HEMODIALYSIS PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NEPHROGENIC SYSTEMIC FIBROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; CONTRAST MEDIA; DIALYSIS; FEMALE; FRANCE; GADOLINIUM; HUMANS; INCIDENCE; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEPHROGENIC FIBROSING DERMOPATHY; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS;

EID: 84893688337     PISSN: 00209996     EISSN: 15360210     Source Type: Journal    
DOI: 10.1097/RLI.0000000000000000     Document Type: Article

References (45)

1. Cowper SE, Robin HS, Steinberg SM, et al. Scleromyxoedema-like cutaneous diseases in renal-dialysis patients. Lancet. 2000;356:1000-1001.
2. Francès C, Senet P, Lipsker D. Nephrogenic systemic fibrosis [in French]. Rev Med Interne. 2011;32:358-362.
3. Cowper SE. Nephrogenic systemic fibrosis: the nosological and conceptual evolution of nephrogenic fibrosing dermopathy. Am J Kidney Dis. 2005;46:763-765.
4. Ledneva E, Janus N, Amet S. Toxicités des chélates de gadolinium chez le patient insuffisant rénal. Sang Thrombose Vaisseaux. 2010;22:90-95.
5. Kucher C, Steere J, Elenitsas R, et al. Nephrogenic fibrosing dermopathy/ nephrogenic systemic fibrosis with diaphragmatic involvement in a patient with respiratory failure. J Am Acad Dermatol. 2006;54(suppl 2):S31-S34.
6. Ting WW, Stone MS, Madison KC, et al. Nephrogenic fibrosing dermopathy with systemic involvement. Arch Dermatol. 2003;139:903-906.
7. DeHoratius DM, Cowper SE. Nephrogenic systemic fibrosis: an emerging threat among renal patients. Semin Dial. 2006;19:191-194.
8. Darwish T, Wood B. Nephrogenic systemic fibrosis: what internists need to know. Mo Med. 2009;106:373-376.
9. Cowper SE. The International Center forNephrogenic Systemic Fibrosis Research (ICNSFR)Web site. Available at: http://www.icnfdr.org. Accessed April 15, 2013.
10. Kendrick-Jones JC, Voss DM, De Zoysa JR. Nephrogenic systemic fibrosis, in patients with end-stage kidney disease on dialysis, in the greater Auckland region, from 2000-2006. Nephrology (Carlton). 2011;16:243-248.
11. Grobner T. Gadolinium-a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant. 2006;21:1104-1108.
12. High WA, Ayers RA, Chandler J, et al. Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol. 2007;56:21-26.
13. Morcos SK. Nephrogenic systemic fibrosis following the administration of extracellular gadolinium based contrast agents: is the stability of the contrast agent molecule an important factor in the pathogenesis of this condition? Br J Radiol. 2007;80:73-76.
14. Thomsen HS. European Society of Urogenital Radiology guidelines on contrast media application. Curr Opin Urol. 2007;17:70-76.
15. Girardi M, Kay J, Elston DM, et al. Nephrogenic systemic fibrosis: clinicopathological definition and workup recommendations. J Am Acad Dermatol. 2011;65:1095-1106.
16. Becker S, Walter S, Witzke O, et al. The German registry for nephrogenic systemic fibrosis: findings from 23 patients. Clin Nephrol. 2010;73:426-430.
17. Perazella MA. Nephrogenic systemic fibrosis, kidney disease, and gadolinium: is there a link? Clin J Am Soc Nephrol. 2007;2:200-202.
18. Fretellier N, Idée JM, Guerret S, et al. Clinical, biological, and skin histopathologic effects of ionic macrocyclic and nonionic linear gadolinium chelates in a rat model of nephrogenic systemic fibrosis. Invest Radiol. 2011;46:85-93.
19. Hope TA, Herfkens RJ, Denianke KS, et al. Nephrogenic systemic fibrosis in patients with chronic kidney disease who received gadopentetate dimeglumine. Invest Radiol. 2009;44:135-139.
20. Khurana A, Runge VM, Narayanan M, et al. Nephrogenic systemic fibrosis: a review of 6 cases temporally related to gadodiamide injection (omniscan). Invest Radiol. 2007;42:139-145.
21. Pietsch H, Raschke M, Ellinger-Ziegelbauer H, et al. The role of residual gadolinium in the induction of nephrogenic systemic fibrosis-like skin lesions in rats. Invest Radiol. 2011;46:48-56.
22. Steger-Hartmann T, Hofmeister R, Ernst R, et al. A review of preclinical safety data for Magnevist (gadopentetate dimeglumine) in the context of nephrogenic systemic fibrosis. Invest Radiol. 2010;45:520-528.
23. Thomsen HS, Morcos SK, Almén T, et al. Nephrogenic systemic fibrosis and gadolinium-based contrast media: updated ESUR Contrast Medium Safety Committee guidelines. Eur Radiol. 2012;23:307-318.
24. Rydahl C, Thomsen HS, Marckmann P. High prevalence of nephrogenic systemic fibrosis in chronic renal failure patients exposed to gadodiamide, a gadolinium-containing magnetic resonance contrast agent. Invest Radiol. 2008;43:141-144.
25. Becker S, Walter S, Witzke O, et al. Application of gadolinium-based contrast agents and prevalence of nephrogenic systemic fibrosis in a cohort of end-stage renal disease patients on hemodialysis. Nephron Clin Pract. 2012;121:c91-c94.
26. Broome DR, Girguis MS, Baron PW, et al. Gadodiamide-associated nephrogenic systemic fibrosis: why radiologists should be concerned. AJR Am J Roentgenol. 2007;188:586-592.
27. Chen W, Huang S-L, Huang C-S, et al. Nephrogenic systemic fibrosis in advanced chronic kidney disease: a single hospital's experience in Taiwan. Eur J Dermatol. 2009;19:44-49.
28. Collidge TA, Thomson PC, Mark PB, et al. Gadolinium-enhanced MR imaging and nephrogenic systemic fibrosis: retrospective study of a renal replacement therapy cohort. Radiology. 2007;245:168-175.
29. Heinz-Peer G, Neruda A, Watschinger B, et al. Prevalence of NSF following intravenous gadolinium-contrast media administration in dialysis patients with endstage renal disease. Eur J Radiol. 2010;76:129-134.
30. Lauenstein TC, Salman K, Morreira R, et al. Nephrogenic systemic fibrosis: center case review. J Magn Reson Imaging. 2007;26:1198-1203.
31. Martin DR, Krishnamoorthy SK, Kalb B, et al. Decreased incidence of NSF in patients on dialysis after changing gadolinium contrast-enhanced MRI protocols. J Magn Reson Imaging. 2010;31:440-446.
32. Othersen JB, Maize JC, Woolson RF, et al. Nephrogenic systemic fibrosis after exposure to gadolinium in patients with renal failure. Nephrol Dial Transplant. 2007;22:3179-3185.
33. Todd DJ, Kagan A, Chibnik LB, et al. Cutaneous changes of nephrogenic systemic fibrosis: predictor of early mortality and association with gadolinium exposure. Arthritis Rheum. 2007;56:3433-3441.
34. Idée JM, Port M, Raynal I, et al. Clinical and biological consequences of transmetallation induced by contrast agents for magnetic resonance imaging: a review. Fundam Clin Pharmacol. 2006;20:563-576.
35. De Campos ROP, Heredia V, Ramalho M, et al. Quarter-dose (0.025 mmol/kg) gadobenate dimeglumine for abdominal MRI in patients at risk for nephrogenic systemic fibrosis: preliminary observations. AJR Am J Roentgenol. 2011;196:545-552.
36. Frenzel T, Lengsfeld P, Schirmer H, et al. Stability of gadolinium-based magnetic resonance imaging contrast agents in human serum at 37 degrees C. Invest Radiol. 2008;43:817-828.
37. Bennett CL, Qureshi ZP, Sartor AO, et al. Gadolinium-induced nephrogenic systemic fibrosis: the rise and fall of an iatrogenic disease. Clin Kidney J. 2012;5:82-88.
38. Alhadad A, Sterner G, Svensson A? , et al. Incidence of nephrogenic systemic fibrosis at a large university hospital in Sweden. Scand J Urol Nephrol. 2012;46:48-53.
39. Reiter T, Ritter O, Prince MR, et al. Minimizing risk of nephrogenic systemic fibrosis in cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2012;14:31.
40. Claudot F, Alla F, Fresson J, et al. Ethics and observational studies in medical research: various rules in a common framework. Int J Epidemiol. 2009; 38:1104-1108.
41. Anon. French annual report of the REIN registry. 2010. Available at: http:// www.soc-nephrologie.org/PDF/enephro/registres/rapport-2010/rapport-2010. pdf. Accessed April 15, 2013.
42. Marckmann P, Skov L, Rossen K, et al. Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol. 2006;17:2359-2362.
43. Barrantes F, Carlson K, Girardi M. Post-exposure inflammatory state and late presentation of NSF: a new concern for exposed patients? Presented as a poster at the Third Annual Scientific Symposium on NSF and GBCA. New Haven, CT: Yale University; 2008.
44. Hashemi P, Sina B, Rietkerk W, et al. The debate between gadolinium versus erythropoietin in a renal transplant patient with nephrogenic systemic fibrosis. J Nephrol. 2012;26:48-54.
45. Janus N, Launay-Vacher V, Karie S, et al. Prevalence of nephrogenic systemic fibrosis in renal insufficiency patients: results of the FINEST study. Eur J Radiol. 2010;73:357-359.